Table 1.

Myeloid neoplasms with STAT5B mutations

Case #	Age	Gender	Diagnosis by WHO classification	WBC (/mcl)	Eosinophilia (Y/N)	PB eosinophils (%)	PB absolute eosinophil count (/mcl)	BM Blast (%)	Abnormal T-cells by flow cytometry	Karyotype	STAT5B mutation(s) (VAF%)	Therapy	Follow up (months)	Outcome
1	77	F	AML with with mutated NPM1	40300	N	1	400	66	Not detected	46,XX[20]	p.N642H (38.9%)	Decitabine, Enasidenib	12	DOD
2	70	F	AML, therapy-related*	2200	N	4	100	34	ND	46,XX[20]	p.N642H (10.1%)	Cytarabine, daunorubicin, HIDAC	24	AWD
3	71	F	AML, NOS**	8000	N	3	200	8	Not detected	46,X,t(X;9)(p22.1;q34.3)[15]/46,XX[5]	p.N642H (12.2%)	CLAG-M, Enasidenib	30	DOD
4	88	M	MDS-RS-SLD	7100	Y	24	1700	4	Not detected	47,XY,+8[16]/46,idem,-Y[8]/46,XY[1]	p.T628S (5.4%); p.V712E (1.8%)	Decitabine, EPO, G-CSF	60	AWD
5	74	M	CMML	17000	Y	14.7	2500	3	Not detected	46,XY[20]	p.N642H (44.9%)	Observation	10	DOC

AML; acute myeloid leukemia. NOS; not otherwise specified. MDS-RS-SLD; myelodysplasic syndrome with ring sideroblasts and single lineage dysplasia. CMML; chronic myelomonocytic leukemia. PB; peripheral blood. BM; bone marrow.

ND; not done. HIDAC; high-dose cytarabine. CLAG-M; Cladribine, Cytarabine, G-CSF, Mitoxantrone. DOD; died of disease. AWD; alive with disease. DOC; died of complications

^*History of marginal zone lymphona, status post chemotherapy

^**Persistent AML, NOS, showing 8% blast in the bone marrow after induction therapy